SBRT for oligoprogressive disease: using the evidence to maximise the benefits.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

1. Clinical outcomes of stereotactic body radiotherapy for spinal metastases with paraspinal extension.Journal of neuro-oncology · 2026
   Article
2. Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC.Frontiers in oncology · 2026
   Article
3. Role of Circulating Tumor DNA Tumor Fraction in Advanced Non-Small Cell Lung Cancer and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study.JCO precision oncology · 2025
   Article
4. Stereotactic radiotherapy for oligometastatic mediastinal lymph-nodes: a multicentre retrospective experience.Clinical & experimental metastasis · 2025
   Article
5. Local Control of Advanced Breast Cancer-Debate in Multidisciplinary Tumor Board.Journal of clinical medicine · 2025
   Article
6. Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2024
   Article

Corrections and comments

• Comment on
  Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.2024

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as